These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10170294)
1. The challenge of integrating monoclonal antibodies into the current healthcare system. Brixner DI; Bull SA Am J Manag Care; 1997 Jun; 3(6):903-11. PubMed ID: 10170294 [TBL] [Abstract][Full Text] [Related]
2. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Smart A; Martin P Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196 [TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. Beware the Medical-Industrial Complex. Stevens CW; Glatstein E Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005 [TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE; J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533 [TBL] [Abstract][Full Text] [Related]
6. The changing environment for technological innovation in health care. Goodman CS; Gelijns AC Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263 [TBL] [Abstract][Full Text] [Related]
9. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues. Mackler BF; Barach M J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898 [TBL] [Abstract][Full Text] [Related]
12. Economics of new oncology drug development. DiMasi JA; Grabowski HG J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942 [TBL] [Abstract][Full Text] [Related]
13. Research and development of drugs and biologic entities. Piascik MM Am J Hosp Pharm; 1991 Oct; 48(10 Suppl 1):S4-13. PubMed ID: 1772113 [TBL] [Abstract][Full Text] [Related]
15. The prospective of the biotechnology industry on changing technology in pathology. Schoepke HG Arch Pathol Lab Med; 1987 Jul; 111(7):596-600. PubMed ID: 3475045 [TBL] [Abstract][Full Text] [Related]
16. The pharmacoeconomics of high-cost biotechnology products. Dana WJ; Farthing K Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236 [TBL] [Abstract][Full Text] [Related]
17. Process economics of industrial monoclonal antibody manufacture. Farid SS J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):8-18. PubMed ID: 16899415 [TBL] [Abstract][Full Text] [Related]
18. Future European health care: cost containment, health care reform and scientific progress in drug research. Emilien G Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136 [TBL] [Abstract][Full Text] [Related]
19. Health economic research on vaccinations and immunisation practices--an introductory primer. Szucs TD Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578 [TBL] [Abstract][Full Text] [Related]
20. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]